Corrigendum to “Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group”

🔗 Access full article via Annals of Oncology

The authors regret that in Table 8, the estimated prevalence of the BRAF V600E mutation in cholangiocarinoma should be 5%, not 50% as reported in the original publication. The corrected Table 8 is given below.